Regeneron Pharmaceuticals Inc
$ 750.57
0.61%
17 Apr - close price
- Market Cap 79,350,120,000 USD
- Current Price $ 750.57
- High / Low $ 758.61 / 746.91
- Stock P/E 18.08
- Book Value 304.65
- EPS 41.51
- Next Earning Report 2026-04-29
- Dividend Per Share $3.52
- Dividend Yield 0.47 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 820.12
- 52 Week Low 474.60
About
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Analyst Target Price
$875.45
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-30 | 2025-10-30 | 2025-08-01 | 2025-04-29 | 2025-02-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-02 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 11.44 | 11.83 | 12.89 | 8.22 | 12.07 | 12.46 | 11.56 | 9.55 | 11.86 | 11.59 | 10.24 | 10.09 |
| Estimated EPS | 10.52 | 9.67 | 8.44 | 8.48 | 11.19 | 11.7 | 10.61 | 10.09 | 10.73 | 10.72 | 9.84 | 9.56 |
| Surprise | 0.92 | 2.16 | 4.45 | -0.26 | 0.88 | 0.76 | 0.95 | -0.54 | 1.13 | 0.87 | 0.4 | 0.53 |
| Surprise Percentage | 8.7452% | 22.3371% | 52.7251% | -3.066% | 7.8642% | 6.4957% | 8.9538% | -5.3518% | 10.5312% | 8.1157% | 4.065% | 5.5439% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 6.21 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|
| Payment Date | 2026-03-05 | 2025-12-05 | 2025-09-03 | 2025-06-06 | 2025-03-20 |
| Amount | $0.94 | $0.88 | $0.88 | $0.88 | $0.88 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: REGN
2026-04-20 08:01:31
First Horizon Corp significantly reduced its stake in Regeneron Pharmaceuticals by 89.4% in the fourth quarter, selling 9,911 shares and holding 1,172 shares valued at $905,000. Meanwhile, other institutional investors adjusted their positions, with some like Brighton Jones LLC and Sei Investments Co. increasing their holdings. Regeneron Pharmaceuticals recently surpassed Q4 earnings estimates, reported revenues of $3.88 billion, and increased its quarterly dividend to $0.94 per share, maintaining a "Moderate Buy" consensus rating among analysts with an average target price near $812.
2026-04-20 07:08:31
AE Wealth Management LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ: REGN) by 36.7% in the fourth quarter, bringing its total to 5,474 shares valued at $4.23 million. This move comes as Regeneron reported stronger-than-expected quarterly earnings and revenue, and raised its quarterly dividend. Despite mixed market views and recent insider selling, institutional ownership remains high at 83.31%, and analysts maintain a "Moderate Buy" consensus rating for the stock.
2026-04-20 01:45:02
Amgen Inc. is strategically positioning itself in the competitive biotechnology landscape by focusing on high-demand obesity treatments, alongside its existing strengths in inflammation and oncology. The company's innovative drug pipeline, including candidates like MariTide for obesity, and its established business model with blockbuster drugs, offer potential for significant revenue growth and a resilient investment for U.S. and global investors. While facing risks from clinical trial outcomes, biosimilar competition, and legislative changes, analysts generally view Amgen positively due to its robust pipeline and dividend reliability.
2026-04-20 00:08:21
Regeneron Pharmaceuticals announced a collaboration with Telix Pharmaceuticals Limited to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership combines Regeneron's expertise in biologics and bispecific antibody discovery with Telix's radiopharmaceutical development platform. The agreement includes an upfront cash payment of $40 million to Telix for access to its manufacturing platform for initial therapeutic programs targeting solid tumors, with options for expanding to additional programs.
2026-04-19 23:09:08
Kymera Therapeutics recently received FDA Fast Track designation for its drug KT-621, intended for eosinophilic asthma, and partner Gilead licensed Kymera's KT-200, triggering a US$45 million milestone payment. These developments validate Kymera's protein degradation platform, potentially boosting investor confidence despite the company's ongoing losses and high R&D spend. The article suggests these events could reshape Kymera's investment narrative, with upcoming Phase 2b data for KT-621 being a key focus for investors.
2026-04-19 20:07:00
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced a collaboration with Telix Pharmaceuticals Limited for the joint development and commercialization of next-generation radiopharmaceutical therapies. This partnership combines Regeneron's biologics expertise with Telix's radiopharmaceutical platform, focusing on solid tumor targets and diagnostic development. Under the agreement, Telix will receive an initial $40 million from Regeneron for access to its manufacturing platform for four therapeutic programs.
